PROJECT SUMMARY/ABSTRACT Asthma affects ~300 million people world-wide and causes hundreds of thousands of deaths annually. Even with the advent of effective biologic agents, many patients remain symptomatic and suffer frequent exacerbations. This is, in part, because of the heterogeneity of asthma pathophysiology; and because of the suboptimal predictive value of therapeutic response biomarkers. Largely because of this, several consortia have been established around the world to improve understanding and management of asthma. In an effort to coordinate the programs of these networks, lead investigators from US and UK consortia have been meeting twice annually, largely with the support of the NHLBI and the Asthma UK and British Lung Foundation Partnership. These meetings have occurred in conjunction with the American Thoracic Society (ATS) and European Respiratory Society (ERS) Conferences. At the 2019 ERS conference, it was concluded that efforts to coordinate these programs were falling short. In particular, collaborative use of databases for testing and validation was not being facilitated; innovation was not being encouraged and pursued – particularly in the case of non-Th2 asthma; and stakeholders around the world were not being encouraged work together to solve problems. The US-UK meetings last only a half-day, do not involve all stakeholders, are not focused on practical solutions to the challenges of collaboration, and do not usually result in actionable innovations. Therefore, the establishment of a new network, the International Collaborative Asthma Network (ICAN), was proposed to be inaugurated with a face-to-face meeting. This meeting is intended to harmonize and use existing networks, rather than to duplicate them. Specific Aims of the first meeting, proposed here, will be as follows: 1) To establish an international collaborative asthma research network entity; 2) To establish international collaborations to test and/or validate innovative hypotheses; 3) To establish international collaborations to develop and translate ideas for new technologies and therapies; 4) To build infrastructure for international collaborations to do innovative studies of personalized severe asthma treatments. 5) To improve communications among all stakeholders. This initial meeting of the ICAN is envisioned to live on after 2021 in the form of subsequent regular meetings and digital platforms for innovation and for data sharing.